Apellis Pharmaceuticals Option Alert: Oct 17 $20 Calls at the Bid: 2500 vs 367 OI; Earnings 7/31 Before Open [est] 

Apellis Pharmaceuticals Option Alert: Oct 17 $20 Calls at the Bid: 2500 @ $2.4 vs 367 OI; Earnings 7/31 Before Open [est] Ref=$18.37

Apellis Pharmaceuticals Bolsa (NASDAQ: APLS)

Apellis Pharmaceuticals (NASDAQ:APLS) Bolsa

APELLIS PHARMACEUTICALS INC

Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals Inc

13 analysts have expressed a variety of opinions on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $30.46, a high estimate of $52.00, and a low estimate of $18.00. Highlighting a 17.68% decrease, the current average has fallen from the previous average price target of $37.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1751487475_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Apellis Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$41.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ryan Deschner</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$20.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$29.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$44.00</td>
<td>-</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$21.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Apellis Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Apellis Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Apellis Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/APLS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Apellis Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Apellis Pharmaceuticals Better</h2>
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
<h3>Apellis Pharmaceuticals's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: Apellis Pharmaceuticals's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -3.21%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Apellis Pharmaceuticals's net margin excels beyond industry benchmarks, reaching -55.29%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Apellis Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -46.96%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Apellis Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -10.9%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 2.86, Apellis Pharmaceuticals faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

APLS

What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals

Morgan Stanley analyst Judah Frommer maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Equal-Weight and raises the price target from $25 to $26.

News

Price Target

Morgan Stanley Maintains Equal-Weight on Apellis Pharmaceuticals, Raises Price Target to $26

WIIM

Apellis Pharmaceuticals shares are trading higher after the company announced a capped royalty purchase agreement with Sobi.

<ul>
<li>Under the companies' 2020 collaboration agreement, Apellis is eligible for tiered royalties on ex-U.S. sales of Aspaveli ranging from high teens to high twenties. Apellis retains exclusive commercialization rights for systemic pegcetacoplan in the United States, where the product is marketed as EMPAVELI.</li>
<li>Apellis to receive $275 million upfront and up to $25 million in milestone payments upon EMA approval in C3G and IC-MPGN</li>
<li>Non-dilutive financing further strengthens Apellis' balance sheet</li>
<li>Apellis retains full U.S. commercialization rights for systemic pegcetacoplan</li>
<li>Transaction underscores shared confidence in the meaningful growth potential in rare kidney diseases</li>
</ul>

Biotech

Health Care

Contracts

General

Apellis Pharmaceuticals Announced A Capped Royalty Purchase Agreement With Sobi Under Which Apellis Will Receive Up To $300M In Exchange For 90% Of Apellis' Future Ex-U.S. Royalties For Aspaveli (Systemic Pegcetacoplan)

<ul>
<li>Robust proteinuria reduction and stable kidney function were maintained across a broad population of patients</li>
<li>No new safety signals were observed</li>
<li>New data presented at late-breaking session at the European Renal Association Congress</li>
<li>Marketing applications for EMPAVELI are under review with the FDA and EMA</li>
</ul>
WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) and Sobi&#xAE; (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI&#xAE; (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part of a late-breaking session at the European Renal Association (ERA) Congress.
In the VALIANT study, EMPAVELI demonstrated a statistically significant 68% proteinuria reduction versus placebo at Week 26, which was sustained at one year. Additionally, patients treated with EMPAVELI continued to achieve stabilization of kidney function as measured by estimated glomerular filtration rate (eGFR).

Apellis Pharma Presents New Data From Open-Label Period Of Phase 3 VALIANT Study, Investigating EMPAVELI For C3 Glomerulopathy And Primary IC-MPGN, At ERA Congress

Apellis Pharmaceuticals shares are trading higher after Wells Fargo raised its price target on the stock from $26 to $29.

Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Equal-Weight and raises the price target from $26 to $29.

Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Raises Price Target to $29

Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $33.47, with a high estimate of $57.00 and a low estimate of $18.00. This current average represents a 13.91% decrease from the previous average price target of $38.88. 
<img src="https://www.benzinga.com/files/images/story/2025/1747936822_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Apellis Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$41.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ryan Deschner</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$20.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$29.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$44.00</td>
<td>-</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$21.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$31.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Apellis Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Apellis Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Apellis Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/APLS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Apellis Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Apellis Pharmaceuticals Better</h2>
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
<h3>Apellis Pharmaceuticals: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Apellis Pharmaceuticals's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -3.21%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Apellis Pharmaceuticals's net margin excels beyond industry benchmarks, reaching -55.29%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Apellis Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -46.96%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -10.9%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Apellis Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 2.86. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and lowers the price target from $49 to $41.

Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $41

Mizuho analyst Graig Suvannavejh maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Neutral and lowers the price target from $30 to $20.

Mizuho Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $20

Raymond James analyst Ryan Deschner downgrades Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) from Strong Buy to Outperform and lowers the price target from $75 to $52.

Downgrades

Raymond James Downgrades Apellis Pharmaceuticals to Outperform, Lowers Price Target to $52

B of A Securities analyst Tazeen Ahmad downgrades Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) from Buy to Neutral and lowers the price target from $41 to $23.

B of A Securities Downgrades Apellis Pharmaceuticals to Neutral, Lowers Price Target to $23

RBC Capital analyst Luca Issi maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Sector Perform and lowers the price target from $21 to $18.

RBC Capital Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $18

Scotiabank analyst Greg Harrison maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Sector Perform and lowers the price target from $28 to $20.

Scotiabank Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $20

Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Equal-Weight and lowers the price target from $30 to $26.

Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $26

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Outperform and lowers the price target from $55 to $47.

Baird Maintains Outperform on Apellis Pharmaceuticals, Lowers Price Target to $47

Needham analyst Joseph Stringer maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and lowers the price target from $40 to $29.

Needham Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $29

U.S. stock futures were higher this morning, with the Dow futures gaining over 300 points on Wednesday.
Shares of Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) fell sharply in today's pre-market trading after the company <a href="https://www.benzinga.com/quote/SRPT/earnings">reported a first-quarter adjusted EPS miss.</a>
Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst consensus estimate of losses of 95 cents. Quarterly revenue came in at $744.86 million, which beat the consensus estimate of $683.36 million.
Sarepta Therapeutics lowered its fiscal 2025 revenue to a new range of $2.3 billion to $2.6 billion.
Sarepta Therapeutics shares tumbled 20.6% to $37.10 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Vestis Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) fell 25.7% to $6.47 in pre-market trading after the company reported worse-than-expected quarterly financial results.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) fell 16.2% to $43.09 in pre-market trading after the company issued second-quarter sales guidance below estimates.</li>
<li>Apellis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) dipped 13.6% to $16.53 in pre-market trading following first-quarter results.</li>
<li>Revolve Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) fell 10.8% to $16.90 in today's pre-market trading after the company reported downbeat quarterly sales.</li>
<li>The Hackett Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCKT#NASDAQ">HCKT</a>) dipped 8.9% to $23.69 in pre-market trading after the company issued weak outlook for the second quarter.</li>
<li>RXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXO#NYSE">RXO</a>) fell 7.6% to $12.70 in pre-market trading.</li>
<li>Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) dipped 7% to $56.94 in pre-market trading after the company postponed its Investor Day amid uncertainty.</li>
<li>Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) declined 6.5% to $98.06 in pre-market trading after the company posted downbeat first-quarter results and lowered its FY25 forecast.</li>
<li>Mercury Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>) fell 5.7% to $47.54 in pre-market trading following weaker-than-expected quarterly earnings.</li>
<li>Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) dipped 5.3% to $86.00 in pre-market trading following downbeat quarterly sales.  </li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45219636/top-2-energy-stocks-that-are-ticking-portfolio-bombs">Top 2 Energy Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

ANET

HCKT

LNTH

MRCY

MRVL

RVLV

SRPT

UPST

VSTS

Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Apellis Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 sales results.

Guidance

Apellis Pharmaceuticals' Cash And Cash Equivalents Of $358.4M As Of March 31, 2025; Projected Revenues And Cash Expected To Be Sufficient To Fund Operations To Profitability

Earnings

Press Releases

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Comments

Apellis Pharmaceuticals

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL